intTypePromotion=1
zunia.vn Tuyển sinh 2024 dành cho Gen-Z zunia.vn zunia.vn
ADSENSE

Quality of life analyses in patients with multiple myeloma: Results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

Chia sẻ: _ _ | Ngày: | Loại File: PDF | Số trang:10

9
lượt xem
1
download
 
  Download Vui lòng tải xuống để xem tài liệu đầy đủ

Selinexor is an oral, selective nuclear export inhibitor. STORM was a phase 2b, single-arm, open-label, multicenter trial of selinexor with low dose dexamethasone in patients with penta-exposed relapsed/refractory multiple myeloma (RRMM) that met its primary endpoint, with overall response of 26% (95% confidence interval [CI], 19 to 35%).

Chủ đề:
Lưu

Nội dung Text: Quality of life analyses in patients with multiple myeloma: Results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

ADSENSE

CÓ THỂ BẠN MUỐN DOWNLOAD

 

Đồng bộ tài khoản
2=>2